Connors Investor Services Inc. trimmed its position in Omnicell, Inc. (NASDAQ:OMCL) by 0.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,467 shares of the company’s stock after selling 296 shares during the quarter. Connors Investor Services Inc. owned 0.12% of Omnicell worth $4,170,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in OMCL. Invesco Ltd. raised its holdings in shares of Omnicell by 79.8% in the 2nd quarter. Invesco Ltd. now owns 779,632 shares of the company’s stock worth $67,072,000 after purchasing an additional 346,029 shares during the period. BlackRock Inc. raised its holdings in shares of Omnicell by 5.7% during the 2nd quarter. BlackRock Inc. now owns 6,413,649 shares of the company’s stock valued at $551,764,000 after buying an additional 344,744 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Omnicell by 709.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 231,236 shares of the company’s stock valued at $18,694,000 after buying an additional 202,682 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Omnicell by 716.6% during the 1st quarter. JPMorgan Chase & Co. now owns 225,620 shares of the company’s stock valued at $18,239,000 after buying an additional 197,990 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Omnicell by 4.6% during the 2nd quarter. Vanguard Group Inc. now owns 4,223,552 shares of the company’s stock valued at $363,352,000 after buying an additional 186,781 shares during the period. Institutional investors own 98.38% of the company’s stock.
Shares of NASDAQ:OMCL traded up $1.08 during mid-day trading on Thursday, hitting $74.72. 2,467 shares of the company traded hands, compared to its average volume of 239,522. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.54 and a current ratio of 2.03. Omnicell, Inc. has a 52-week low of $56.96 and a 52-week high of $92.59. The firm’s 50 day simple moving average is $71.73 and its 200 day simple moving average is $78.40. The firm has a market cap of $3.02 billion, a P/E ratio of 48.67, a PEG ratio of 2.36 and a beta of 1.13.
In other Omnicell news, EVP Dan S. Johnston sold 9,929 shares of Omnicell stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $85.47, for a total transaction of $848,631.63. Following the sale, the executive vice president now directly owns 31,505 shares in the company, valued at approximately $2,692,732.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Randall A. Lipps sold 5,000 shares of Omnicell stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $70.30, for a total value of $351,500.00. Following the sale, the chairman now owns 140,506 shares in the company, valued at $9,877,571.80. The disclosure for this sale can be found here. Insiders have sold a total of 22,479 shares of company stock worth $1,746,040 over the last 90 days. 2.77% of the stock is owned by company insiders.
Several equities research analysts recently commented on OMCL shares. ValuEngine downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Zacks Investment Research upgraded Omnicell from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a report on Monday, July 29th. BidaskClub downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Thursday, June 27th. Finally, Craig Hallum upgraded Omnicell from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a report on Friday, July 26th. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Omnicell currently has an average rating of “Buy” and an average target price of $79.11.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Read More: Certificate of Deposit (CD)
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.